Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses
Jordan R. Barrett(National Institute for Health and Care Research), Catherine Green(University of Oxford), Mustapha Bittaye(University of Oxford), Yama F Mujadidi(University of Oxford), Brian Angus(University of Oxford), Jack Mellors(Centre for Human Genetics), Stephen Taylor(Medway School of Pharmacy), Marion Watson(University of Oxford), Breeze E. Cavell(Public Health England), Kelly Thomas(Public Health England), Eleanor Berrie(University of Oxford), Duncan Bellamy(University of Oxford), Richard Tarrant(University of Oxford), Matthew D. Snape(University of Oxford), Elizabeth Clutterbuck(University of Oxford), Katie Ewer(University of Oxford), Christine S. Rollier(University of Oxford), Alison M. Lawrie(University of Oxford), Parvinder K. Aley(University of Oxford), Christina Dold(University of Oxford), Lisa Stockdale(University of Oxford), Ian Poulton(University of Oxford), Michelle Fuskova(University of Oxford), Xinxue Liu(University of Oxford), Daniel Jenkin(University of Oxford), Daniel Wright(University of Oxford), Rebecca Makinson(University of Oxford), Angela M. Minassian(National Institute for Health and Care Research), Marije K. Verheul(Leiden University Medical Center), Meera Madhavan(University of Oxford), Alexander D. Douglas(University of Oxford), Pedro M. Folegatti(University of Oxford), Simon Kerridge(University of Oxford), Sagida Bibi(University of Oxford), Ciarán Gilbride(University of Oxford), Andrew Gorringe(Public Health England), Miles W. Carroll(Institute of Human Genetics), Nick J. Edwards(University of Oxford), Rachel Halkerston(Public Health England), Sandra Belij‐Rammerstorfer(University of Oxford), Bassam Hallis(Public Health England), Jennifer Hill(University of Oxford), Amy Flaxman(University of Oxford), Merryn Voysey(Stratasys (Israel)), Hannah Robinson(University of Oxford), Emma Plested(University of Oxford), Aline Linder(University of Oxford), Maria Moore(University of Oxford), Rinn Song(University of Oxford), Maheshi Ramasamy(University of Oxford)
Cited by 340
Related Papers
Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial
|The Lancet|2020|2.6k
Broad and strong memory CD4+ and CD8+ T cells induced by SARS-CoV-2 in UK convalescent individuals following COVID-19
|Nature Immunology|2020|1.4k
Multiplex PCR method for MinION and Illumina sequencing of Zika and other virus genomes directly from clinical samples
|Nature Protocols|2017|1.3k